DrugPatentWatch Database Preview
SEYSARA Drug Patent Profile
Email this page to a colleague
When do Seysara patents expire, and when can generic versions of Seysara launch?
Seysara is a drug marketed by Almirall and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-seven patent family members in twenty countries.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Seysara
Seysara will be eligible for patent challenges on October 1, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 9, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SEYSARA
| International Patents: | 67 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Clinical Trials: | 1 |
| Patent Applications: | 63 |
| Drug Prices: | Drug price information for SEYSARA |
| What excipients (inactive ingredients) are in SEYSARA? | SEYSARA excipients list |
| DailyMed Link: | SEYSARA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for SEYSARA
Generic Entry Date for SEYSARA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SEYSARA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Derm Research, PLLC | Phase 4 |
Pharmacology for SEYSARA
| Drug Class | Tetracycline-class Drug |
| Mechanism of Action | P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for SEYSARA
US Patents and Regulatory Information for SEYSARA
SEYSARA is protected by five US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEYSARA is ⤷ Try it Free.
This potential generic entry date is based on patent ⤷ Try it Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SEYSARA
Substituted tetracycline compounds
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(met- hyl)amino)-methyl] acid amide and methods of using the same
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(met- hyl)amino)-methyl] acid amide and methods of using the same
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
FDA Regulatory Exclusivity protecting SEYSARA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try it Free
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-001 | Oct 1, 2018 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-003 | Oct 1, 2018 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-002 | Oct 1, 2018 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Almirall | SEYSARA | sarecycline hydrochloride | TABLET;ORAL | 209521-001 | Oct 1, 2018 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SEYSARA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017132775 | ⤷ Try it Free |
| Lithuania | 2120963 | ⤷ Try it Free |
| Japan | 2019081802 | ⤷ Try it Free |
| Hong Kong | 1170218 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
